Skip to content

Efficacy and safety of Chonglian oral liquid in the treatment of influenza fever: a prospective, multicenter, randomized, controlled trial

Efficacy and safety of Chonglian oral liquid in the treatment of influenza fever: a prospective, multicenter, randomized, controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042823
Enrollment
Unknown
Registered
2021-01-29
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Group 1:Chonglian oral liquid
Group 2:Chonglian oral liquid+Oseltamivir capsule
Group 3:Shufeng Jiedu Capsule
Group 4:Oseltamivir capsule

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of influenza fever and the criteria of traditional Chinese medicine for the syndrome of wind heat attacking the health or the syndrome of heat toxin attacking the lung; (2) Aged between 15 and 65 years; (3) Acute onset, course within 48 hours; (4) Temperature between 38 to 39.5 degree C; (5) Hemogram: the total number of leukocytes is less than 10.00 x 10^9/L, and the number of neutrophils is less than 80%; (6) Informed consent, voluntary participate.

Exclusion criteria

Exclusion criteria: 1. Fever caused by viral infection of lower respiratory tract and other diseases of respiratory, digestive, urinary and blood system; 2. Pregnancy or lactate woman; 3. Have serious primary cardiovascular disease, lung disease, liver disease, kidney disease, hematology disease, or serious diseases affecting their survival, such as tumor or AIDS.

Design outcomes

Primary

MeasureTime frame
Body temperature (armpit temperature);

Secondary

MeasureTime frame
Clinical symptoms and signs; Liver and kidney function;Urine routine;

Countries

China

Contacts

Public ContactLi Zegeng

The First Affiliated Hospital of Anhui University of Chinese Medicine

li6609@126.com+86 13805516609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026